Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial

Overview of attention for article published in The Lancet Respiratory Medicine, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
twitter: 32 X users

wikipedia: 2 Wikipedia pages
reddit: 1 Redditor

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Brensocatib has no impact on COVID-19 clinical outcomes | Latest news for Doctors, Nurses and Pharmacists - journalbreak

journalbreak.Com, 02 Oct 2022

The results of the STOP-COVID study presented at ERS 2022 showed no clinical outcome advantage with the dipeptidyl peptidase-1 (D…

Brensocatib has no impact on COVID-19 clinical outcomes | Latest news for Doctors, Nurses and Pharmacists - daytonewsofficial

Day To News.com, 02 Oct 2022

The results of the STOP-COVID study presented at ERS 2022 showed no clinical benefit with the dipeptidyl peptidase-1 (DPP-1…

DPP-1 Blocker a Bust in Severe COVID

MedPage Today, 08 Sep 2022

Meeting Coverage > ERS Deaths in hospitalized patients significantly higher with oral brensocatib, trial finds by James Lopilato…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.